Compare American International Group Inc (AIG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs Viatris Inc — how do they compare? American International Group Inc trades at $76.02 (market cap $40.42B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: American International Group Inc is far larger — about 2.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| AIG | VTRS | |
|---|---|---|
Market Cap | $40.42B | $18.69B |
Sector | Financials | Health |
52-Week High | $86.59 | $17.86 |
52-Week Low | $71.89 | $9.49 |
Enterprise Value | $48.06B | $30.80B |
Dividend Yield | 2.59% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $76.33, down 1.65% on the day, with a bearish technical signal and neutral oscillators. The company shows strong earnings momentum with three consecutive quarterly beats (Q4 2025: $1.96 vs $1.90 expected, Q1 2026: $2.11 vs $1.89, Q2 2026: $2.00 vs $1.92) and maintains a 11.12% net income margin. Recent news highlights CEO Eric Anderson discussing geopolitical opportunities and strong Q2 results with 10% adjusted EPS growth.
AIG presents a mixed outlook with solid fundamentals and earnings consistency offset by bearish technicals. The 12-month consensus price target of $89.00 suggests 16.6% upside potential, supported by 39% analyst buy ratings. Key risks include competitive pricing pressure in North American property insurance and market volatility. The stock's current valuation at 14.11 P/E appears reasonable given earnings growth trajectory.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
